Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DBVTNASDAQ:ERYPNASDAQ:GRPHNASDAQ:LGST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$9.40-4.6%$9.14$2.20▼$12.78$257.47M-0.63191,126 shs22,359 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AGRPHGraphite Bio$13.89$2.01▼$4.26$185.20M0.2282,405 shs435,164 shsLGSTSemper Paratus Acquisition$4.51$4.52$4.08▼$12.03$71.35M-0.0830,930 shs12,596 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies0.00%+3.30%+11.77%+110.76%+93.81%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%GRPHGraphite Bio0.00%0.00%0.00%0.00%0.00%LGSTSemper Paratus Acquisition0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDBVTDBV Technologies3.258 of 5 stars3.35.00.00.02.52.50.6ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AGRPHGraphite BioN/AN/AN/AN/AN/AN/AN/AN/ALGSTSemper Paratus AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies 2.50Moderate Buy$14.7556.91% UpsideERYPERYTECH Pharma 0.00N/AN/AN/AGRPHGraphite Bio 0.00N/AN/AN/ALGSTSemper Paratus Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ERYP, GRPH, LGST, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025DBVTDBV TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell$7.255/27/2025DBVTDBV TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/27/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.005/5/2025DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $16.005/1/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV Technologies$4.15M62.04N/AN/A$1.42 per share6.62ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88GRPHGraphite BioN/AN/AN/AN/A$3.15 per shareN/ALGSTSemper Paratus AcquisitionN/AN/A$0.33 per share13.74($1.10) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$113.92M-$4.92N/AN/AN/A-3,249.99%-278.24%-140.54%7/29/2025 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AGRPHGraphite Bio-$124.65M-$2.23N/AN/AN/AN/A-33.12%-27.96%N/ALGSTSemper Paratus Acquisition$4.41MN/A0.00∞N/AN/A-21.83%3.10%N/ALatest ERYP, GRPH, LGST, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/11/2025Q4 2024DBVTDBV TechnologiesN/A-$1.10N/A-$1.10N/A$0.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AGRPHGraphite BioN/AN/AN/AN/AN/ALGSTSemper Paratus AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A0.720.72ERYPERYTECH Pharma0.323.653.65GRPHGraphite BioN/A39.2039.20LGSTSemper Paratus AcquisitionN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%ERYPERYTECH Pharma1.09%GRPHGraphite Bio54.32%LGSTSemper Paratus AcquisitionN/AInsider OwnershipCompanyInsider OwnershipDBVTDBV Technologies1.44%ERYPERYTECH Pharma1.94%GRPHGraphite Bio38.40%LGSTSemper Paratus Acquisition56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies8027.39 million27.00 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableGRPHGraphite Bio658.24 million35.87 millionNot OptionableLGSTSemper Paratus Acquisition2,02115.82 million6.86 millionNot OptionableERYP, GRPH, LGST, and DBVT HeadlinesRecent News About These CompaniesLGST.3850 Immigration Law (Formerly 41.385)April 26, 2024 | uml.eduLGST.3760 Family Law (Formerly 41.376)March 27, 2024 | uml.eduTevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGNFebruary 14, 2024 | finance.yahoo.comTevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGNFebruary 14, 2024 | globenewswire.comSPAC Semper Paratus shareholders okay merger with Tevogen BioFebruary 1, 2024 | msn.comSemper Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen BioFebruary 1, 2024 | finance.yahoo.comSemper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on NasdaqJanuary 24, 2024 | finance.yahoo.comSemper Paratus Acquisition Corp (LGST)January 10, 2024 | investing.comTevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business CombinationJanuary 5, 2024 | finance.yahoo.comWith a 56% stake, Semper Paratus Acquisition Corporation (NASDAQ:LGST) insiders have a lot riding on the companyDecember 5, 2023 | finance.yahoo.comSemper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing RequirementSeptember 29, 2023 | finance.yahoo.comSemper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio IncSeptember 14, 2023 | finance.yahoo.comTevogen to go public via merger with SPAC Semper ParatusJune 30, 2023 | msn.comBiotech firm Tevogen Bio enters $1.2 bln SPAC deal for US listingJune 29, 2023 | reuters.comSemper Paratus Acquisition Corp Class AJune 27, 2023 | morningstar.comSemper Paratus Acquisition Corporation (LGST)April 17, 2023 | finance.yahoo.comSemper Paratus Acq Stock (NASDAQ:LGSTU), Trade IdeasFebruary 24, 2023 | benzinga.comSemper Paratus Acquisition Corp. Cl AJanuary 25, 2023 | wsj.comSaba Capital Management, L.P. Buys FTAC Zeus Acquisition Corp, Semper Paratus Acquisition Corp, ...February 18, 2022 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERYP, GRPH, LGST, and DBVT Company DescriptionsDBV Technologies NASDAQ:DBVT$9.40 -0.45 (-4.57%) Closing price 06/20/2025 03:46 PM EasternExtended Trading$9.59 +0.19 (+2.02%) As of 06/20/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.ERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Graphite Bio NASDAQ:GRPHGraphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.Semper Paratus Acquisition NASDAQ:LGSTSemper Paratus Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to acquire companies operating in the transportation, supply chain, and logistics industries. Semper Paratus Acquisition Corporation was incorporated in 2021 and is based in New York, New York. Semper Paratus Acquisition Corporation operates as a subsidiary of Ssvk Associates, Llc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
